SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 123 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.11 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $34,703,918 | -31.6% | 2,390,077 | -1.4% | 2.36% | -39.9% |
| Q2 2023 | $50,737,083 | +5.6% | 2,424,132 | +6.6% | 3.92% | -13.9% |
| Q1 2023 | $48,037,693 | -3.4% | 2,274,512 | +16.4% | 4.55% | -22.0% |
| Q4 2022 | $49,742,330 | +90.8% | 1,954,512 | +80.1% | 5.84% | +68.0% |
| Q3 2022 | $26,076,000 | +54.7% | 1,085,142 | +23.9% | 3.48% | +3.4% |
| Q2 2022 | $16,857,000 | +38.3% | 876,156 | +24.9% | 3.36% | +4.3% |
| Q1 2022 | $12,190,000 | +22.9% | 701,356 | +54.8% | 3.22% | +13.8% |
| Q4 2021 | $9,918,000 | – | 453,091 | – | 2.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |